• Botanix secures ~A$48 million (US$30 million) debt facility from Kreos Capital
• Facility will support commercialization of Sofdra™ and other platform expansion opportunities
• Combined with recent A$40 million capital raising, Botanix is well-positioned to execute on its plans

Botanix Pharmaceuticals Ltd (ASX: BOT) has entered into a loan facility of up to the euro equivalent of US$30 million with Kreos Capital VII (UK) Limited and its related entities. The facility provides for an initial tranche of ~A$31 million (US$20 million) available upon closing and a further ~A$15.5 million (US$10 million) available to be drawn down up to and including 1 October 2026. The facility will be used for general working capital and other permitted commercialization and platform expansion purposes. The loan is secured by the assets of Botanix and its subsidiaries. Kreos Capital has the option to convert part of the loan into fully paid ordinary shares in the company under certain conditions. The facility enhances Botanix's financial flexibility to support its growth and strategic initiatives, following the recent successful A$40 million capital raising to accelerate the commercial launch of Sofdra™ (sofpironium) topical gel. Combined with the cash on hand at the end of the last quarter (~A$28 million), Botanix is well funded to support Sofdra through to profitability and to opportunistically pursue expansions to the platform.

Botanix is well positioned to execute on its commercialization and development plans for Sofdra™ and other platform expansion opportunities, supported by the ~A$48 million (US$30 million) debt facility and recent A$40 million capital raising.